Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Creative pattern made with a syringe on pastel pink background. Vaccine for Coronavirus infection. Pandemic concept.

COVID-19

FDA assembles vaccine experts to update COVID-19 formulation

The FDA will convene its vaccines advisory panel to discuss seasonal COVID-19 vaccines—a surprise move after Health Secretary and vaccine skeptic Robert F. Kennedy, Jr. overhauled a separate vaccine committee.

May 27, 2026

2 min read

Tristan Manalac

Contemporary art collage showing a hand giving a thumbs down surrounded by red arrows pointing down, concept of negative feedback and bad review

Breast cancer

AstraZeneca’s breast cancer pill hit with review delay after negative adcomm vote

An FDA advisory committee recently voted against approving AstraZeneca’s oral SERD drug camizestrant for certain patients with advanced breast cancer. It is unclear when the new target action date for the drug will be.

May 27, 2026

4 min read

Tristan Manalac

Trend artwork sketch montage 3D collage of young man hold laptop climb up pile coins economy savings cash trade finance career promotion.

Cancer

Kura’s encouraging cancer drug data could unlock $2B market opportunity

Nearly 80% of patients saw tumor shrinkage after being treated with Kura Oncology’s darlifarnib plus Bristol Myers Squibb’s Krazati, findings Mizuho analysts say could open up a $2 billion opportunity for the biotech.

May 27, 2026

2 min read

Tristan Manalac

Illustration of cardboard box filled with office supplies, a computer keyboard, lamp, and a potted plant

Layoff Tracker

J&J trims New Jersey headcount by 56

Follow along as BioSpace tracks job cuts and restructuring initiatives.

May 27, 2026

56 min read

BioSpace Editorial Staff

Isometric Office chair with vacancy sign isolated on blue background. Employment, vacancy and hiring job vector concept

Regulatory

Makary’s reforms will live on at FDA even as leadership turns over

Under the temporary reign of top food executive Kyle Diamantas, the FDA will sustain programs initiated by former Commissioner Marty Makary, including the Commissioner’s National Priority Voucher initiative.

May 27, 2026

2 min read

Tristan Manalac

Podcast

Lilly wheels and deals, Moderna gets boost on hantavirus scare, ASCO excitement builds

Eli Lilly continues to spend its GLP-1 landfall with four new deals in the past week, including three in the vaccine space; the obesity leader also touted surgery-like results for its next-gen weight loss drug; Moderna’s stock climbs on the hantavirus “fear trade”; and in oncology, all eyes are on Revolution at ASCO this week.

May 27, 2026

2 min read

Jef Akst

Three businessmen discussing work isolating another businessman

Career Advice

Curse of the straight-A student

The people most trusted to deliver are not always the ones invited to shape direction. Executive coach Angela Justice examines why the habits that build a career can eventually limit advancement.

May 27, 2026

4 min read

Angela Justice

Insights

Germany can produce biotech winners. Europe must back them better.

Strong science and early support are not enough on their own. Europe needs more capital depth, cross-border investor backing and a lighter policy framework to keep companies scaling at home, according to two venture capitalists.

May 27, 2026

4 min read

Jennifer C. Smith-Parker